SCHEMBL3960709

SCHEMBL3960709

O=C(Nc1ccc(F)cc1)N1CCc2nccnc2C1c1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 8/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3960706 1.00 TRPM8 (1.00) TRPM8
SCHEMBL4183269 1.00 TRPM8 (1.00) TRPM8
SCHEMBL4067195 0.86 TRPM8 (1.00) TRPM8
SCHEMBL4054683 0.86 TRPM8 (1.00) TRPM8
SCHEMBL3956643 0.86 TRPM8 (1.00) TRPM8
SCHEMBL4062190 0.86 TRPM8 (1.00) TRPM8
SCHEMBL3958128 0.86 TRPM8 (1.00) TRPM8
SCHEMBL3956663 0.85 TRPM8 (0.80) TRPM8
SCHEMBL3956670 0.85 TRPM8 (0.80) TRPM8
SCHEMBL4076118 0.85 TRPM8 (0.73) TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US claimed
WO-2009038812-A1 CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2009-03-26 WO disclosed
WO-2009038812-A1 CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2009-03-26 WO disclosed
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US disclosed
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US disclosed
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082358-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 TRPM8 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.